Bonuccelli, Gloria <br/><br/>
Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.  [electronic resource] 

 -  Cell cycle (Georgetown, Tex.)  May 2007 
 - 1242-8 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1551-4005 
<br/><br/><label>Standard No.: </label>10.4161/cc.6.10.4182  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Boronic Acids--pharmacology<br/>Bortezomib<br/>Dipeptides--pharmacology<br/>Dystrophin--metabolism<br/>Dystrophin-Associated Proteins--metabolism<br/>Male<br/>Mice<br/>Mice, Inbred mdx<br/>Microscopy, Fluorescence<br/>Muscle, Skeletal--metabolism<br/>Muscular Dystrophy, Duchenne--drug therapy<br/>NF-kappa B--metabolism<br/>Protease Inhibitors--pharmacology<br/>Pyrazines--pharmacology